Kiely David G, Kennedy Norman S, Pirzada Omar, Batchelor Sheila A, Struthers Allan D, Lipworth Brian J
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK.
Respir Med. 2005 Oct;99(10):1286-91. doi: 10.1016/j.rmed.2005.02.029.
Pulmonary thromboembolism (PTE) occurs in a wide variety of clinical settings and presents a diagnostic challenge to clinicians, often requiring extensive imaging of the vascular bed. Management increasingly requires accurate risk stratification to rapidly identify those with massive and submassive PTE requiring different therapeutic strategies such as thrombolysis. Provision of a rapid blood test that improves diagnostic certainty and helps stratify risk could therefore bridge the gap between uncertainty and delivery of immediate early life-saving treatment.
One hundred and fourteen consecutive patients with suspected PTE underwent prospective evaluation. Venous blood samples were obtained from an unselected group referred for ventilation-perfusion scintigraphy. B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal pro-ANP (N-ANP) were measured by radioimmunoassay using commercially available kits. The scans were classified into three groups according to standard criteria (PIOPED); normal scan (N) (n=20), low/intermediate probability (L/I) of PTE (n=77) and high probability (H) of PTE (n=17). Comparisons were also made between patients with high probability scans who died (n=3) and those who survived (n=14). Values are quoted for the median and interquartile ranges. There were statistically significant differences between groups for levels of (a) BNP (P<0.001): N=6.7 pmol/l (5.6-11.9), L/I=12.5 pmol/l (6.7-28.2) and H=18.5 pmol/l (12.6-74.6); (b) ANP (P<0.005): N=12.6 pmol/l (7.1-16.0), L/I=19.51 pmol/l (12.5-28.2) and H=19.1 pmol/l (15.7-31.7) and (c) N-ANP (P<0.05): N=177 pmol/l (119-200), L/I=302 pmol/l (152-576) and H=322 pmol/l (223-563). Levels of BNP and ANP were significantly (P<0.05) higher in patients with high probability scans and a diagnosis of PTE who died (n=3) than in those who survived (n=14); BNP: 91.6 pmol/l (77.5-336.2) vs. 14.4 pmol/l (11.9-27.4) and ANP 32.5 pmol/l (21.7-105.5) vs. 17.6 pmol/l (15.2-19.3), respectively.
PTE is associated with significantly elevated levels of the natriuretic peptides ANP, BNP and N-ANP. Increasing ventilation-perfusion mismatch on scintigraphy corresponds to incremental increases in the levels of ANP, BNP and N-ANP found. These peptides, and in particular BNP, may add to the diagnosis by rapidly providing a probability of PE before dedicated imaging studies can be performed. Natriuretic peptides require further study to establish their role in identifying a high-risk group who may benefit from early treatments such as thrombolysis.
肺血栓栓塞症(PTE)发生于多种临床情况,给临床医生带来诊断挑战,常需对血管床进行广泛成像检查。治疗越来越需要准确的危险分层,以迅速识别那些患有大面积和次大面积PTE且需要不同治疗策略(如溶栓)的患者。因此,提供一种能提高诊断确定性并有助于危险分层的快速血液检测,可弥合不确定性与立即进行早期挽救生命治疗之间的差距。
114例连续的疑似PTE患者接受了前瞻性评估。从未经选择的一组接受通气-灌注闪烁扫描的患者中采集静脉血样。使用市售试剂盒通过放射免疫分析法测定B型利钠肽(BNP)、心房利钠肽(ANP)和N末端前ANP(N-ANP)。扫描结果根据标准标准(PIOPED)分为三组:正常扫描(N)(n = 20)、PTE低/中度可能性(L/I)(n = 77)和PTE高度可能性(H)(n = 17)。还对扫描高度可能性且死亡的患者(n = 3)和存活的患者(n = 14)进行了比较。数值以中位数和四分位数间距表示。各组之间(a)BNP水平有统计学显著差异(P < 0.001):N = 6.7 pmol/l(5.6 - 11.9),L/I = 12.5 pmol/l(6.7 - 28.2),H = 18.5 pmol/l(12.6 - 74.6);(b)ANP水平有统计学显著差异(P < 0.005):N = 12.6 pmol/l(7.1 - 16.0),L/I = 19.51 pmol/l(12.5 - 28.2),H = 19.1 pmol/l(15.7 - 31.7);(c)N-ANP水平有统计学显著差异(P < 0.05):N = 177 pmol/l(119 - 200),L/I = 302 pmol/l(152 - 576),H = 322 pmol/l(223 - 563)。扫描高度可能性且诊断为PTE的死亡患者(n = 3)的BNP和ANP水平显著高于存活患者(n = 14)(P < 0.05);BNP分别为:91.6 pmol/l(77.5 - 336.2)对比14.4 pmol/l(11.9 - 27.4),ANP分别为32.5 pmol/l((21.7 - 105.5)对比17.6 pmol/l(15.2 - 19.3)。
PTE与利钠肽ANP、BNP和N-ANP水平显著升高相关。闪烁扫描中通气-灌注不匹配增加与所发现的ANP、BNP和N-ANP水平的递增相对应。这些肽类,尤其是BNP,可能在进行专门成像研究之前通过快速提供PE可能性来辅助诊断。利钠肽需要进一步研究以确定它们在识别可能从溶栓等早期治疗中获益的高危组中的作用。